Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II study of L-DOS47 in combination with Doxorubicin for the treatment of metastatic pancreatic cancer

Trial Profile

A Phase I/II study of L-DOS47 in combination with Doxorubicin for the treatment of metastatic pancreatic cancer

Planning
Phase of Trial: Phase I/II

Latest Information Update: 14 Nov 2018

At a glance

  • Drugs L-DOS 47 (Primary)
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms LDOS006
  • Most Recent Events

    • 14 Nov 2018 New trial record
    • 01 Nov 2018 According to a Helix BioPharma media release, the Company is currently completing the study protocol and will be looking to submit to the FDA, in the coming months, an investigational new drug (IND) application.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top